FOXP3 expression is related to high ki-67 index and poor prognosis in lymph node-positive breast cancer patients

Oncology (Switzerland)

Volumn 85, Issue 2, 2013, Pages 128-136

  Kim, Min Hwan ^a   Koo, Ja Seung ^a   Lee, Soohyeon ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Breast cancer; Forkhead box protein; Ki 67; Prognosis

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; TRANSCRIPTION FACTOR FOXP3;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; FEMALE; HEALTH STATUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; HISTOLOGY; HUMAN TISSUE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 84883380771     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000351473     Document Type: Article

References (21)

1. Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W, Liu Y, Wang Y, Liu X, Chan MW, Liu JQ, Love R, Liu CG, Godfrey V, Shen R, Huang TH, Yang T, Park BK, Wang CY, Zheng P, Liu Y: Foxp3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 2007; 129: 1275-1286.
2. Chen GY, Chen C, Wang L, Chang X, Zheng P, Liu Y: Cutting edge: broad expression of the FoxP3 locus in epithelial cells: a caution against early interpretation of fatal inflammatory diseases following in vivo depletion of FoxP3-expressing cells. J Immunol 2008; 180: 5163-5166.
3. Wang L, Liu R, Li W, Chen C, Katoh H, Chen GY, McNally B, Lin L, Zhou P, Zuo T, Cooney KA, Liu Y, Zheng P: Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell 2009; 16: 336-346.
4. Zuo T, Liu R, Zhang H, Chang X, Liu Y, Wang L, Zheng P, Liu Y: FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J Clin Invest 2007; 117: 3765-3773.
5. Liu R, Wang L, Chen G, Katoh H, Chen C, Liu Y, Zheng P: FOXP3 up-regulates p21 expression by site-specific inhibition of histone deacetylase 2/histone deacetylase 4 association to the locus. Cancer Res 2009; 69: 2252-2259.
6. Ladoire S, Mignot G, Dalban C, Chevriaux A, Arnould L, Rebe C, Apetoh L, Boidot R, Penault-Llorca F, Fumoleau P, Roche H, Spielmann M, Levy C, Lortholary A, Eichler F, Mesleard C, Bonnetain F, Ghiringhelli F: FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial. Ann Oncol 2012; 23: 2552-2561.
7. Li W, Katoh H, Wang L, Yu X, Du Z, Yan X, Zheng P, Liu Y: FOXP3 regulates sensitivity of cancer cells to irradiation by transcriptional repression of BRCA1. Cancer Res 2013; 73: 2170-2180.
8. Overbeck-Zubrzycka D, Kirby JA, Ali S, Lennard TW: FOXP3 regulates metastatic spread of breast cancer via control of expression of CXCR4 chemokine receptor. Cancer Prev Res (Phila) 2010; 3:A30.
9. Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Menard S, Tagliabue E, Balsari A: FOXP3 expression and overall survival in breast cancer. J Clin Oncol 2009; 27: 1746- 1752.
10. Nair S, Aldrich AJ, McDonnell E, Cheng Q, Aggarwal A, Patel P, Williams MM, Boczkowski D, Lyerly HK, Morse MA, Devi GR: Immunologic targeting of FOXP3 in inflammatory breast cancer cells. PLoS One 2013; 8:e53150.
11. Ladoire S, Arnould L, Mignot G, Coudert B, Rebe C, Chalmin F, Vincent J, Bruchard M, Chauffert B, Martin F, Fumoleau P, Ghiringhelli F: Presence of FOXP3 expression in tumor cells predicts better survival in HER2- overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 2011; 125: 65-72.
12. Kim D, Jung W, Koo JS: The expression of ERCC1, RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypes. J Korean Med Sci 2011; 26: 352-359.
13. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF: Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009; 27: 1323-1333.
14. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, Panel M: Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747.
15. Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, Beavo JA, Rudensky AY: FOXP3-dependent programme of regulatory Tcell differentiation. Nature 2007; 445: 771-775.
16. Niu J, Jiang C, Li C, Liu L, Li K, Jian Z, Gao T: Foxp3 expression in melanoma cells as a possible mechanism of resistance to immune destruction. Cancer Immunol Immunother 2011; 60: 1109-1118.
17. Hinz S, Pagerols-Raluy L, Oberg HH, Ammerpohl O, Grussel S, Sipos B, Grutzmann R, Pilarsky C, Ungefroren H, Saeger HD, Kloppel G, Kabelitz D, Kalthoff H: Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 2007; 67: 8344-8350.
18. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
19. Hancock WW, Ozkaynak E: Three distinct domains contribute to nuclear transport of murine Foxp3. PLoS One 2009; 4:e7890.
20. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA: Ki-67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010; 11: 174-183.
21. Munzone E, Botteri E, Sciandivasci A, Curigliano G, Nole F, Mastropasqua M, Rotmensz N, Colleoni M, Esposito A, Adamoli L, Luini A, Goldhirsch A, Viale G: Prognostic value of Ki-67 labeling index in patients with nodenegative, triple-negative breast cancer. Breast Cancer Res Treat 2012; 134: 277-282.